{"product_id":"vtak-ansoff-analysis","title":"(VTAK) Catheter Precision, Inc. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDive Deeper Into the Growth Paths Behind the Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Catheter Precision, Inc. Ansoff Matrix Analysis shows how the company can grow via market penetration, market development, product development, and diversification, and is designed for strategy, investment, or planning use; the sample on this page is a real preview of the analysis, not just marketing copy. Purchase the full version to receive the complete, ready-to-use Ansoff Matrix tailored to Catheter Precision, Inc.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVIVO adoption in U.S. electrophysiology labs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCatheter Precision’s VIVO is already aimed at idiopathic ventricular arrhythmia mapping in otherwise healthy hearts, so U.S. market penetration depends on wider use inside existing EP labs and cardiology groups. The main lever is physician familiarity with non-invasive 3D pre-procedure mapping, which can shorten planning before ablation. In 2025–2026, the story is less about new use cases and more about converting current lab workflow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhysician education on ventricular arrhythmia localization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVIVO helps electrophysiologists map idiopathic ventricular arrhythmias before the procedure, so market penetration depends on showing how it fits into existing diagnostic workflows. Clinical education is key because doctors are more likely to move from trial use to repeat use when they see clearer localization and faster case setup. For Catheter Precision, Inc., that makes training a sales tool, not just a support function.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital workflow fit for LockeT\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLockeT fits hospital workflow because it sells through existing procedural supply channels and can be added to routine access-site and closure steps without changing the core procedure. In this category, simple use, repeat ordering, and clinician preference drive adoption, so a device that saves time and feels easy to standardize has a clear penetration path. Catheter Precision can grow share by getting LockeT specified in more cath lab and EP closure protocols.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAmigo use in established catheter-control settings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAmigo’s market penetration is strongest in existing catheterization and EP centers that already use remote or assisted control tools, because it plugs into current workflows rather than forcing a new setup. The remote robotic arm improves precision, consistency, and operator control during catheter handling, which matters most in high-volume labs. In 2025-2026, the focus is retention and deeper use inside the installed base, not broad new-site adoption.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets existing cath and EP centers\u003c\/li\u003e\n\u003cli\u003eUses current remote-control workflows\u003c\/li\u003e\n\u003cli\u003eRaises precision and consistency\u003c\/li\u003e\n\u003cli\u003eSupports operator control in routine cases\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCross-sell across the EP product portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCatheter Precision, Inc. can boost penetration by cross-selling its 3-product EP set: VIVO, LockeT, and Amigo. One hospital account can buy more than 1 device, so the same physician and hospital buying path can lift revenue per account and lower selling cost per sale. This matters because EP tools are often chosen by the same care team, which makes bundle-style adoption easier.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e3 products: VIVO, LockeT, Amigo\u003c\/li\u003e\n\u003cli\u003eSell into the same hospital account\u003c\/li\u003e\n\u003cli\u003eMore devices can raise account revenue\u003c\/li\u003e\n\u003cli\u003eShared physicians can speed adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDeepen EP Lab Adoption with Repeat VIVO, LockeT, and Amigo Use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMarket penetration for Catheter Precision, Inc. is about deeper use of VIVO, LockeT, and Amigo in existing EP and cath labs, not new use cases. The best path is training, protocol fit, and repeat ordering inside current hospital accounts. One account can adopt more than one product, so share of wallet can rise fast.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFocus\u003c\/th\u003e\n\u003cth\u003ePenetration lever\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eVIVO\/LockeT\/Amigo\u003c\/td\u003e\n\u003ctd\u003eExisting labs, training, repeat use\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAnalyzes Catheter Precision, Inc.’s growth strategy across existing and new products and markets using the Ansoff Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear Catheter Precision, Inc. Ansoff Matrix Analysis to quickly pinpoint growth options and reduce strategic uncertainty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, traceable bibliography that validates Catheter Precision’s Ansoff Matrix assumptions for products, markets, and expansion decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpansion from early adopters to broader U.S. hospital networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCatheter Precision’s market development case is about moving its same EP tools from early adopters into larger U.S. hospital networks. That matters in a market where atrial fibrillation affects about 6 million Americans, and the U.S. has roughly 6,000 hospitals, so each network win can widen reach fast. The product stays the same; the buyer set expands from niche EP users to system-level health care buyers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReach into community and regional EP centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVIVO and Amigo fit community and regional electrophysiology centers that treat ventricular arrhythmia cases outside large academic hospitals. This is a market development move: Catheter Precision, Inc. can widen reach by selling the same tools into more sites, not by changing the product set. The growth lever is site expansion, since many EP procedures still sit in higher-volume referral hubs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroader use within cardiac arrhythmia care pathways\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCatheter Precision, Inc. can widen use across the arrhythmia care pathway, not just a single ablation step. With atrial fibrillation affecting over 59 million people worldwide, products that support pre-procedure mapping, catheter control, and intra-procedural guidance can reach more cases without changing the portfolio. That expands the addressable market while staying in cardiac arrhythmia care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAdditional U.S. geographies through field commercialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCatheter Precision, Inc., based in Fort Mill, South Carolina, can grow by widening field commercialization across the U.S. The same VIVO and LockeT products can reach new regional EP and cardiac surgery accounts without changing the core offer. This fits market development: more geography, same product.\u003c\/p\u003e\n\u003cp\u003eNational hospital density supports the move: the U.S. has 6,000+ hospitals and 200,000+ practicing cardiologists, so even small account wins can add revenue fast.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExpand into undercovered U.S. regions\u003c\/li\u003e\n\u003cli\u003eUse field reps to open new accounts\u003c\/li\u003e\n\u003cli\u003eKeep the product mix unchanged\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAccount expansion in physician-led and hospital-led buying channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCatheter Precision can grow by moving beyond current users into new physician groups, hospital systems, and arrhythmia service lines. That matters because hospitals and physicians are separate buying centers, so one sale does not automatically open the other; account expansion can widen access without changing the core product.\u003c\/p\u003e\n\u003cp\u003eFor market development, the goal is simple: add new accounts, then expand inside them. The clearest targets are electrophysiology teams, hospital-led care networks, and procedural units that manage arrhythmia care.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew account types: physician groups\u003c\/li\u003e\n\u003cli\u003eHospital systems and IDNs\u003c\/li\u003e\n\u003cli\u003eArrhythmia care service lines\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCatheter Precision Expands Reach Through New U.S. Accounts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCatheter Precision, Inc. is using market development to sell VIVO, Amigo, and LockeT into more U.S. EP and cardiac surgery accounts without changing the product set. With about 6,000 U.S. hospitals and 200,000+ cardiologists, even small account wins can lift reach fast. The move is geography and buyer expansion, not product change.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. hospitals\u003c\/td\u003e\n\u003ctd\u003e6,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCardiologists\u003c\/td\u003e\n\u003ctd\u003e200,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore tactic\u003c\/td\u003e\n\u003ctd\u003eNew accounts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eCatheter Precision, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNext-generation VIVO mapping refinements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVIVO is Catheter Precision, Inc.'s lead product, so next-gen mapping should sharpen chamber localization, cut setup time, and fit EP lab workflows. In idiopathic ventricular arrhythmia cases, small gains matter because precise site-of-origin calls can reduce repeat studies and procedural drag. Better accuracy and usability can lift adoption and support premium pricing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmigo control and precision upgrades\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmigo is a robotic arm for catheter control, so product development can focus on tighter precision, steadier motion, and easier operator handling in EP procedures. The most natural first buyers are existing hospital users, since they already know the workflow and can upgrade without changing systems. For Catheter Precision, Inc., this is a low-friction 2025-2026 path to deepen use of a 1-platform product rather than build a new market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLockeT line extensions for procedural use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLockeT fits procedural support in the hospital and EP market, so line extensions can expand use without leaving the core customer base. Adding new sizes, variants, or sterile package options can match more cases and lower switching friction in cath labs. That matters because Catheter Precision’s growth path here is depth, not breadth, inside a specialty workflow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIntegrated EP workflow solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCatheter Precision’s product development can tie its 3 core areas: mapping, catheter control, and suture retention, into one integrated EP workflow. That would cut handoffs, simplify use for hospital teams, and support faster physician adoption by reducing steps across the ablation process.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOne workflow, fewer device swaps\u003c\/li\u003e\n\u003cli\u003eLower training burden for staff\u003c\/li\u003e\n\u003cli\u003eBetter fit for EP lab routines\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSoftware and digital enhancements for non-invasive planning\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCatheter Precision, Inc. can use product development to make VIVO stronger by improving 3D views, cleaner reporting, and faster pre-procedure planning. In 2025, its revenue was still small, so digital upgrades matter more than new-market bets because they can lift value without heavy hardware spending.\u003c\/p\u003e\n\u003cp\u003eBetter software can help doctors review scar maps, mark targets, and share plans before ablation. That is useful because VIVO is non-invasive, so the product wins on speed, clarity, and workflow support rather than surgery. One good upgrade can make the tool easier to adopt in busy electrophysiology labs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eImprove 3D visualization\u003c\/li\u003e\n\u003cli\u003eAutomate clinical reports\u003c\/li\u003e\n\u003cli\u003eSupport pre-case planning\u003c\/li\u003e\n\u003cli\u003eDifferentiation without new markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCatheter Precision’s 2025-2026 Growth Play: Deepen, Don’t Expand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCatheter Precision, Inc. should use product development to deepen VIVO, Amigo, and LockeT inside the same EP workflow. The 2025-2026 play is clearer software, tighter control, and more line variants, so the company grows from 3 core products without chasing new customers.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003e2025-2026 move\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVIVO\u003c\/td\u003e\n\u003ctd\u003eBetter 3D mapping\u003c\/td\u003e\n\u003ctd\u003eFaster, clearer planning\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmigo\u003c\/td\u003e\n\u003ctd\u003eMore precise motion\u003c\/td\u003e\n\u003ctd\u003eEasy hospital adoption\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLockeT\u003c\/td\u003e\n\u003ctd\u003eMore sizes\/packaging\u003c\/td\u003e\n\u003ctd\u003eLess switching friction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdjacent cardiac rhythm management products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCatheter Precision, Inc. already focuses on electrophysiology and arrhythmias, so diversification into adjacent cardiac rhythm management products is a natural step beyond its current three-device set. With the global cardiac rhythm management market still driven by atrial fibrillation, which affected about 59.7 million people in 2019, nearby products could deepen clinical reach without leaving its core niche. The key risk is capital: new device development and FDA pathways can stretch a small company fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroader interventional cardiac procedural tools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCatheter Precision, Inc. already has 3 procedural technologies in VIVO, LockeT, and Amigo, so diversification can extend it into more interventional cardiac tools used in catheter-based care. That would move the Company beyond pure mapping and control into adjacent steps like positioning, access, and workflow support. With only 3 core products today, adding one or two adjacent tool lines could widen the installed-use case without changing the catheter lab setting.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-invasive cardiac diagnostics beyond ventricular mapping\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVIVO shows Catheter Precision, Inc. can build non-invasive cardiac tech, which supports a diversification move. A next step could be software for cardiac rhythm evaluation, widening the product set beyond ventricular mapping. That matters because atrial fibrillation affects about 5.1 million U.S. adults, opening a larger diagnostic market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAccessory and support-device categories outside core mapping\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLockeT shows Catheter Precision, Inc. can sell into the procedural support layer, not just mapping. That opens diversification into adjacent support devices beyond robotic catheter control, giving hospitals a broader vendor stack and reducing reliance on one-use tools. The company’s latest public portfolio still centers on a small set of products, so even one new support-device line could widen revenue exposure.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMoves beyond core mapping\u003c\/li\u003e\n\u003cli\u003eAdds adjacent procedure support\u003c\/li\u003e\n\u003cli\u003eFits hospital buying bundles\u003c\/li\u003e\n\u003cli\u003eBroadens product base\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePlatform expansion into new clinical workflow segments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCatheter Precision, Inc.'s current lineup is tightly linked to electrophysiology, so moving into new clinical workflow segments would be a true diversification play, not a small extension. That is the furthest Ansoff step from its current market focus because it would target different buyers, hospital committees, and reimbursement paths. One clean sign of the challenge: the company still has to win in a niche workflow before it can credibly jump into another.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFurthest move from current EP focus\u003c\/li\u003e\n\u003cli\u003eNeeds new buyers and workflows\u003c\/li\u003e\n\u003cli\u003eHigher commercial and regulatory risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversification Is Catheter Precision's Riskiest Growth Bet\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDiversification for Catheter Precision, Inc. means moving beyond electrophysiology into adjacent cardiac workflow tools, but it is the riskiest Ansoff step because it needs new buyers, new reimbursement, and more capital. With 3 products now, even one new line could widen use cases, yet FDA and launch risk stay high.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCurrent portfolio\u003c\/td\u003e\n\u003ctd\u003e3 products\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAtrial fibrillation\u003c\/td\u003e\n\u003ctd\u003e59.7 million people, 2019\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. AF burden\u003c\/td\u003e\n\u003ctd\u003e5.1 million adults\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey risk\u003c\/td\u003e\n\u003ctd\u003eCapital and regulatory load\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235185664265,"sku":"vtak-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/vtak-ansoff-matrix.webp?v=1785735667","url":"https:\/\/dcfanalyst.com\/products\/vtak-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}